DermTech (NASDAQ:DMTK) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.64) by 6.25 percent. This is a 36 percent decrease over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $3.03 million which missed the analyst consensus estimate of $3.41 million by 11.14 percent. This is a 122.47 percent increase over sales of $1.36 million the same period last year.
Bill Gates Invests Heavily In Buffett’s Berkshire, And Also These 3 High-Yielding Stocks
As many investors enjoy reviewing the 13F filings from hedge funds and activist investors, one portfolio that many investors love to discuss is that of the Bill & Melinda Gates Foundation.
